Cadrenal Therapeutics (Nasdaq: CVKD) Granted FDA Fast Track Designation for Tecarfarin for Prevention of Systemic Thromboembolism of Cardiac Origin in Patients with End-Stage Renal Disease and Atrial Fibrillation

PONTE VEDRA, Fla., Jan. 23, 2023 -- (Healthcare Sales & Marketing Network) -- Cadrenal Therapeutics (Nasdaq: CVKD), a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug designation, anno... Biopharmaceuticals, FDA Cadrenal Therapeutics, tecarfarin, thromboembolism, ESRD , AFib
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news